Ahmedabad-based Zydus Lifesciences Ltd has inked a pact with precision diagnostics company Myriad Genetics from the USA to introduce globally validated cancer-risk assessment and prognostic tests in India. These include the MyRisk Hereditary Cancer Test, MyChoice HRD Plus Test for ovarian cancer, and Prolaris Prognostic Test for prostate cancer.
The collaboration aims to expand access to personalised, evidence-based cancer care by enabling clinicians to identify hereditary risk, understand tumour biology, and guide treatment decisions based on genomic insights, said a statement here.
Calling the agreement as a major step in expanding access to precision diagnostic tests for cancer treatment in India, Dr. Sharvil P Patel, Managing Director, Zydus, said, “The prostate and ovarian cancer tests help doctors with actionable insights to develop personalised treatment plans, predict disease progression, arrive at treatment decisions and streamline clinical workflows."
“We are also bringing a test which will help identify hereditary risks in patients and their families. Enabling access to these critical diagnostic tests will benefit patients in getting better clinical outcomes and support their fight against cancer.”
Brian Donnelly, Chief Commercial Officer, Myriad Genetics, added, “This collaboration with Zydus is an important step forward in expanding precision oncology across India.
“Myriad tests aim to empower clinicians with actionable information to assess risk, understand tumour biology, and guide truly personalised care with greater clarity, confidence, and hope as they navigate critical health decisions.”
As per agreement, Zydus will exclusively market and build awareness among clinicians for three Myriad platforms that are widely used in North America, Europe and major cancer centres worldwide.
The tests will support personalised prevention and treatment through advanced genomic insights. The MyRisk Hereditary Cancer Test is a comprehensive germline multigene panel that analyses 63 clinically significant genes, including BRCA1/2, PALB2, ATM, TP53, MLH1 and MSH2, to estimate lifetime cancer risk and guide prevention and screening strategies for breast, ovarian, prostate, pancreatic, colorectal, melanoma and other hereditary cancers.
Its RiskScore tool further combines genetic and clinical data to predict five-year and lifetime breast cancer risk, added the statement.
The MyChoice HRD Plus Test is the most comprehensive tumour test for determining HRD status based on the assessment of genomic alterations in genes such as BRCA1 and BRCA2 and Genomic Instability Score (GIS) status using Myriad’s proprietary algorithm. It enables healthcare professionals to identify patients with advanced ovarian cancer who are more likely to respond to treatment with targeted therapies.
The Prolaris Test, an RNA-based gene expression assay, quantifies tumour aggressiveness, supports treatment decisions for localised prostate cancer and estimates a patient’s 10-year risk of metastasis and disease-specific mortality.
The launch comes amid a rise in cancer incidence in India and increasing interest in precision oncology to improve outcomes and reduce treatment burden.
Zydus Lifesciences Ltd, an innovation-led life-sciences group with a global presence, employs around 29,000 people, including 1,500 scientists engaged in R&D, and is focused on expanding access to high-quality and advanced healthcare solutions.
Myriad Genetics is a leading precision medicine and molecular diagnostics company developing tests that assess hereditary cancer risk, guide treatment decisions and support personalised care pathways across medical specialties.
